2023年中国31省新诊断HIV感染者传播性耐药横断面调查
2023年4至6月在中国31个省级行政区对新诊断HIV感染者进行横断面调查,成功对6654份血浆样本进行耐药基因型检测。总体传播性耐药(TDR)患病率为11.4%(95%CI 10.6%-12.2%),其中依非韦伦/奈韦拉平(EFV/NVP)TDR为6.5%。多因素分析显示非汉族、未知传播途径和CD4≥500 cells/μL与TDR相关,高等教育降低TDR风险。
要点
- 新诊断HIV感染者总体TDR为11.4%,EFV/NVP TDR为6.5%。
- NNRTI类TDR最高(7.9%),NRTI、PI、INSTI分别为0.8%、2.4%、1.0%。
- 非汉族、未知传播途径、CD4≥500 cells/μL与TDR风险升高相关。
核心结论
- 中国新诊断HIV感染者TDR超过10%,EFV/NVP TDR超过5%;及时监测TDR并调整ART方案对减轻耐药对疗效的影响至关重要。
研究设计与样本
- 2023年4至6月在中国31个省级行政区开展的横断面调查,收集新诊断HIV感染者的 demographic 信息和血样,基于部分pol序列用Stanford HIV耐药数据库和HIV-TRACE分析TDR及分子传播网络,用logistic回归识别TDR相关因素。
- 成功对6654人的血浆样本进行HIV耐药基因型检测。
主要发现
- 总体TDR患病率为11.4%(95%CI 10.6%-12.2%)。
- 对NNRTI、NRTI、PI和INSTI的耐药率分别为7.9%、0.8%、2.4%和1.0%。
- 对EFV/NVP的TDR为6.5%。
- 根据监测耐药突变列表,对总药物、NNRTI、NRTI、PI和INSTI的TDR患病率分别为8.2%、6.4%、1.0%、0.7%和0.4%。
- 多因素分析显示TDR与非汉族(AOR 1.45,95%CI 1.17-1.79)、未知传播途径(AOR 2.56,95%CI 1.33-4.90)和CD4≥500 cells/μL(AOR 1.29,95%CI 1.05-1.58)相关;高中及以上教育较小学教育降低TDR风险(AOR 0.77)。
关键数值与推荐
- 总体TDR患病率11.4%(95%CI 10.6%-12.2%)。
- NNRTI耐药7.9%,NRTI耐药0.8%,PI耐药2.4%,INSTI耐药1.0%。
- EFV/NVP TDR为6.5%。
- 监测耐药突变列表下总TDR 8.2%,NNRTI 6.4%,NRTI 1.0%,PI 0.7%,INSTI 0.4%。
- 非汉族AOR 1.45(95%CI 1.17-1.79),未知传播途径AOR 2.56(95%CI 1.33-4.90),CD4≥500 cells/μL AOR 1.29(95%CI 1.05-1.58),高中及以上教育AOR 0.77。
临床怎么用
- 对新诊断HIV感染者及时监测TDR并据此调整ART方案,以减轻耐药对疗效的影响。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Transmitted drug resistance (TDR) may compromise the effect of antiretroviral therapy (ART), highlighting the necessity for continuous monitoring. METHODS: The study was conducted across 31 provincial-level administrative divisions of China. Demographic information and blood samples were collected from participants at diagnosis of human immunodeficiency virus (HIV) infection between April and June 2023. TDR and molecular transmission networks were analyzed based on partial pol sequences via the Stanford HIV drug resistance database and HIV-TRACE, respectively. Logistic regression was utilized to identify factors associated with TDR. RESULTS: HIV drug resistance genotyping was successfully performed on plasma samples from 6654 individuals. The overall TDR prevalence was 11.4% (95% confidence interval [CI], 10.6%-12.2%). Resistance to nonnucleoside reverse transcriptase inhibitors (NNRTIs), nucleoside reverse transcriptase inhibitors (NRTIs), protease inhibitors (PIs), and integrase strand transfer inhibitors (INSTIs) was 7.9%, 0.8%, 2.4%, and 1.0%, respectively. TDR to efavirenz/nevirapine (EFV/NVP) was 6.5%. According to the surveillance drug resistance mutation list, the prevalence of TDR to total, NNRTIs, NRTIs, PIs, and INSTIs was 8.2%, 6.4%, 1.0%, 0.7%, and 0.4%. Multivariable analysis linked TDR to non-Han ethnicity (adjusted odds ratio [AOR], 1.45 [95% CI, 1.17-1.79]), unknown transmission routes (AOR, 2.56 [95% CI, 1.33-4.90]), and CD4 ≥500 cells/μL (AOR, 1.29 [95% CI, 1.05-1.58]). Higher education (high school or more) reduced TDR odds (AOR, 0.77 vs primary education). CONCLUSIONS: TDR among people with newly diagnosed HIV in China exceeds 10%, with EFV/NVP TDR >5%. Timely monitoring of TDR and adjustment of ART regimens are essential to mitigate the impact of drug resistance on treatment efficacy.
引用
- Hao J, Liu X, Wang D, et al. Transmitted HIV-1 Drug Resistance Among Newly Diagnosed Individuals in 31 Provincial-Level Administrative Divisions in China in 2023: A Cross-sectional Survey. Clin Infect Dis. 2025. PMID: 40295173. doi:10.1093/cid/ciaf159
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。